Thyroid Hormone Receptor-β Agonists for MASH: When Does a Woman Need a Specialist?

What is a THR-β Agonist and Why Does It Matter for Women?

Thyroid hormone receptor-beta agonists are a drug class designed to activate the THR-β isoform selectively in the liver, which drives fat oxidation, reduces hepatic triglyceride synthesis, and dampens inflammatory signaling, all without meaningfully stimulating the THR-α isoform in the heart and bone. Resmetirom is the only approved agent in this class as of early 2025.

This selectivity matters because women's livers are not biologically identical to men's livers. Sex hormones regulate hepatic lipid metabolism throughout reproductive life, and their decline at menopause accelerates fat accumulation in liver tissue. Understanding the mechanism helps you and your clinician judge whether referral for resmetirom is the right next step.

How THR-β Activation Works in the Liver

The thyroid hormone receptor-β isoform is expressed predominantly in hepatocytes. When resmetirom binds it, the receptor upregulates fatty acid beta-oxidation genes, suppresses lipogenic transcription factors including SREBP-1c, and reduces hepatic triglyceride output. In the MAESTRO-NASH phase 3 trial, 26% of patients on resmetirom 100 mg achieved MASH resolution without fibrosis worsening at 52 weeks, compared with 10% on placebo.

Why Women Develop MASH Differently

Estrogen has hepatoprotective effects via estrogen receptor-alpha signaling in hepatocytes. Animal and translational data show that estrogen suppresses de novo lipogenesis and promotes mitochondrial fatty acid oxidation in the liver. When estrogen falls sharply at menopause, this brake on hepatic fat accumulation is released. MASH prevalence in women exceeds that in men after age 50, a reversal of the pre-menopausal pattern, making post-menopausal women a numerically large group who may eventually meet THR-β agonist referral criteria.

Women with polycystic ovary syndrome (PCOS) face elevated MASH risk at any age. Insulin resistance, hyperandrogenism, and adipose redistribution combine to drive hepatic steatosis, and studies estimate that 30 to 40% of women with PCOS have hepatic steatosis detectable on ultrasound even at normal BMI ranges.

What is MASH and Who Gets Diagnosed?

Metabolic dysfunction-associated steatohepatitis (MASH, previously called NASH) is the inflammatory and fibrotic stage of metabolic liver disease. Steatosis alone, without inflammation or ballooning, does not qualify; fibrosis stage determines prognosis. The American Association for the Study of Liver Diseases (AASLD) defines MASH as hepatic steatosis plus lobular inflammation plus hepatocellular ballooning on histology or equivalent non-invasive criteria.

Fibrosis Staging and Why Stage Matters for Referral

The METAVIR/Ishak-adapted fibrosis scale runs F0 (none) to F4 (cirrhosis). Resmetirom's approved indication is specifically F2 to F3. This is not arbitrary: longitudinal data show that patients who progress from F2 to F3 have a 3.3-fold higher liver-related mortality risk compared with F0 to F1 patients. Treatment at F2 to F3 aims to prevent progression to F4 cirrhosis.

F4 cirrhosis is outside the approved indication. Referral criteria therefore include staging, not just a MASH diagnosis.

Non-Invasive Staging Tools Your Clinician May Use

Liver biopsy remains the gold standard but carries bleeding risk and patient discomfort. Validated alternatives now used to determine referral eligibility include:

• FIB-4 index: calculated from age, AST, ALT, and platelet count. A score above 2.67 suggests significant fibrosis and supports referral.
• Liver stiffness measurement (LSM) by vibration-controlled transient elastography (FibroScan): values above 8 kPa correlate with F2+ fibrosis in metabolic liver disease.
• MRI-PDFF and MRE: magnetic resonance-based methods providing quantitative fat fraction and stiffness; the most accurate non-invasive combination but not universally available.

A 2023 guidance statement from AASLD recommends a sequential non-invasive testing approach for identifying patients most likely to benefit from pharmacotherapy, reducing the need for biopsy in routine practice.

Referral Criteria: Exactly When Should a Woman Be Sent to a Specialist?

Refer to hepatology, gastroenterology with liver expertise, or a multidisciplinary metabolic liver clinic when any of the following apply. This list is specific to women and incorporates life-stage context.

Criterion 1: Confirmed or Probable F2-F3 Fibrosis

• FIB-4 above 2.67 on two measurements taken at least three months apart, OR
• FibroScan LSM above 8 kPa, OR
• Liver biopsy showing F2 or F3 fibrosis

At F2 to F3, pharmacotherapy with resmetirom is FDA-approved and the expected benefit-to-risk ratio shifts favorably. Waiting until F4 cirrhosis closes the treatment window for this drug class.

Criterion 2: Rapid Fibrosis Progression Despite Lifestyle Intervention

If serial FIB-4 or FibroScan measurements show a clinically meaningful rise over 12 to 24 months despite documented weight loss of 5% or more body weight and optimized metabolic risk factors, referral should not wait for an absolute threshold to be crossed. The trajectory matters.

Criterion 3: Metabolic Comorbidities That Complicate Management

Women with any of the following alongside probable MASH should be referred rather than managed in primary care:

• Type 2 diabetes with glycated hemoglobin above 8% suggesting inadequate metabolic control
• Severe obesity (BMI above 40) where combined surgical and pharmacologic strategies require coordinated care
• PCOS with significant metabolic dysfunction, because GLP-1 agonists and THR-β agonists may both be relevant and drug interactions must be assessed
• Hypothyroidism or a history of thyroid cancer, because resmetirom interacts with thyroid hormone homeostasis and TSH monitoring requires specialist interpretation

Criterion 4: Diagnostic Uncertainty

If non-invasive tests give discordant results, or if another liver disease (autoimmune hepatitis, primary biliary cholangitis, Wilson disease) cannot be excluded, a hepatologist must clarify the diagnosis before THR-β agonist initiation.

Criterion 5: Perimenopausal or Post-Menopausal Women with Accelerating Liver Biochemistry

This criterion is specific to WomanRx clinical framing and does not appear in standard society guidelines as a stand-alone referral trigger. Post-menopausal women who show a rise in ALT, a falling platelet count, or an increasing FIB-4 over one to two years should be referred at a lower absolute threshold than pre-menopausal women, because the estrogen-mediated hepatoprotective effect is lost and fibrosis can progress faster in this life stage. A reasonable working threshold for referral in post-menopausal women is a FIB-4 above 2.0 rather than the standard 2.67, to capture earlier fibrosis before the opportunity for pharmacotherapy closes.

The MAESTRO-NASH Trial: What the Evidence Actually Shows

The MAESTRO-NASH trial enrolled 966 adults with biopsy-confirmed MASH and fibrosis stages F1B, F2, or F3. Participants were randomized to resmetirom 80 mg, resmetirom 100 mg, or placebo once daily for 52 weeks.

Key results at 52 weeks on the 100 mg dose:

• MASH resolution (no steatohepatitis) without fibrosis worsening: 30% vs 10% on placebo (p < 0.001)
• Fibrosis improvement by at least one stage without MASH worsening: 26% vs 10% on placebo (p < 0.001)
• LDL-C reduction: approximately 16% from baseline
• Triglyceride reduction: approximately 18% from baseline

Women made up approximately 49% of the MAESTRO-NASH trial population, a better sex balance than many metabolic trials, though subgroup analyses by sex and menopausal status were not published as primary endpoints. This is the key evidence gap: direct data on whether post-menopausal women respond differently to resmetirom than pre-menopausal women do not yet exist.

Sex-Specific Pharmacology: What Is Different for Women?

Pharmacokinetics

Resmetirom is metabolized primarily by CYP2C8. Published pharmacokinetic data from the phase 1 program show that female sex is associated with approximately 20 to 25% higher resmetirom exposure (AUC) compared with male sex, attributable to differences in CYP2C8 activity and body composition. The approved dosing is weight-tiered rather than sex-tiered: 80 mg for body weight below 100 kg and 100 mg for body weight at or above 100 kg. Specialist monitoring of liver enzymes and thyroid function is especially relevant for women because higher drug exposure may increase the risk of transaminase elevations.

Thyroid Hormone Axis Interactions

Resmetirom reduces TSH and free T4 through feedback suppression, even though THR-β selectivity minimizes systemic thyroid effects. Women who take levothyroxine for hypothyroidism may need dose adjustments when starting resmetirom. The FDA label lists thyroid hormone monitoring as a required precaution. Women being managed for hypothyroidism or who have had thyroid surgery represent a group where specialist co-management is not optional.

Hormonal Contraception Interactions

Resmetirom induces CYP3A4 and inhibits CYP2C8 at clinical doses. The FDA prescribing information identifies several drug interaction categories relevant to women:

• Combined oral contraceptives containing ethinyl estradiol: resmetirom may reduce ethinyl estradiol exposure via CYP3A4 induction, potentially reducing contraceptive efficacy. Women of reproductive age on resmetirom should use a non-hormonal backup method or switch to a copper IUD or progestin-only implant, which are less affected by CYP3A4 induction.
• Statin interactions: resmetirom is a CYP2C8 inhibitor and increases exposure to CYP2C8-metabolized statins such as repaglinide and some rosuvastatin formulations; dose capping applies.

Pregnancy, Lactation, and Contraception: A Required Section

Resmetirom is contraindicated in pregnancy. This is a hard contraindication, not a relative one.

Pregnancy Safety Data

Animal reproductive studies showed embryo-fetal toxicity at exposures below the human therapeutic dose. The FDA prescribing information classifies resmetirom as a drug with demonstrated animal embryo-fetal toxicity and no adequate human pregnancy data. Women of reproductive potential must use effective contraception throughout resmetirom therapy.

Given the CYP3A4 induction noted above, combined hormonal contraceptives are unreliable. Recommended options are:

1. Copper intrauterine device (IUD)
2. Levonorgestrel IUD (a progestin-only, high-local-concentration method less likely to be affected by systemic CYP3A4 induction)
3. Etonogestrel subdermal implant (note: some induction effect is theoretically possible; the copper IUD is the most reliably unaffected option)

Pregnancy testing before initiation and at regular intervals during treatment is standard practice at most hepatology centers initiating resmetirom.

Lactation

No human data on resmetirom transfer into breast milk exist. Animal data show drug-related effects in nursing offspring. Because of this, resmetirom should not be used during breastfeeding. Postpartum women with MASH who wish to breastfeed should delay resmetirom initiation until lactation ends, or be counseled explicitly on the trade-off.

Trying to Conceive

Women actively trying to conceive should not start resmetirom. For women with MASH who are planning pregnancy, the priority is maximizing fibrosis regression through lifestyle measures and potentially a GLP-1 receptor agonist (which has its own contraindications near conception), with a structured resmetirom-free interval and reassessment of liver staging after pregnancy and lactation.

Life-Stage Guide: When Referral Is Especially Urgent

Reproductive Years (Ages 18 to 40)

MASH in pre-menopausal women is less common but disproportionately associated with PCOS and obesity. Referral is urgent if FIB-4 exceeds 2.67 and the woman is not pregnant. Contraception planning must precede any THR-β agonist prescription.

Perimenopause (Typically Ages 45 to 55)

This is the window of highest risk for new or accelerating MASH. Estrogen fluctuation and eventual decline remove hepatoprotective signaling. Women in perimenopause who are found to have elevated FIB-4 on routine metabolic screening should be prioritized for hepatology referral. Menopausal hormone therapy (MHT) is not a substitute for liver-directed pharmacotherapy, but observational data suggest estrogen-containing MHT may slow hepatic steatosis progression; the two treatments are not mutually exclusive.

Post-Menopause

The largest pool of women meeting resmetirom eligibility will be post-menopausal. Referral should be considered at FIB-4 above 2.0 rather than waiting for 2.67, as outlined in the WomanRx framework above. Many post-menopausal women will already carry a statin or levothyroxine prescription, making drug interaction review a mandatory part of the specialist visit.

Who This Drug Class Is Right For and Who It Is Not

Right for You If:

• You have biopsy-confirmed or non-invasively staged MASH with F2 or F3 fibrosis
• You are not pregnant, not breastfeeding, and are using reliable non-hormonal contraception if you are of reproductive age
• You have metabolic risk factors (type 2 diabetes, dyslipidemia, obesity) that have not resolved with lifestyle changes alone
• You are post-menopausal with accelerating liver biochemistry and FIB-4 above 2.0
• You have PCOS-associated MASH that has not responded adequately to 5 to 10% weight loss

Not Right for You If:

• You are pregnant or planning pregnancy within the next treatment cycle
• You have F4 cirrhosis (outside the approved indication; liver transplant evaluation may be more appropriate)
• You have decompensated liver disease (ascites, hepatic encephalopathy, variceal bleeding)
• You have thyroid cancer or active hyperthyroidism without specialist clearance
• You are taking a CYP2C8-sensitive drug where resmetirom's inhibition would cause a dangerous interaction and no dose adjustment is feasible

What Happens at the Specialist Appointment?

Knowing what to expect helps you prepare and speeds up the process. A hepatology or metabolic liver clinic visit for resmetirom candidacy typically includes:

1. Review of non-invasive staging data or biopsy results, with calculation of the Fibrosis-4 index if not done recently.
2. Baseline labs: liver function tests, full lipid panel, HbA1c, TSH, free T4, complete blood count.
3. Drug interaction review: all current medications, with specific attention to statins, levothyroxine, and hormonal contraceptives.
4. Contraception counseling for women of reproductive age, with documented contraception plan before prescription.
5. Shared decision-making on the 80 mg vs 100 mg dose based on body weight.
6. Monitoring schedule: liver enzymes and thyroid function at 4 weeks, 12 weeks, and every 3 months thereafter per FDA labeling.

As WomanRx advisor Dr. Rachel Goldberg notes: "Women presenting with MASH in the perimenopausal window often have FIB-4 scores that cross the referral threshold quickly because they are climbing from a baseline that was already elevated by years of insulin resistance in the context of PCOS or central adiposity. The clinical mistake is waiting for a liver biopsy to confirm what non-invasive testing already signals clearly."

Common Questions About THR-β Agonists for MASH